BIONET Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	19.75	21.97	45.3	53.97
Short-Term Investments	1,055	1,155	458	-
Trading Asset Securities	62.54	37.72	21.02	-
Cash & Short-Term Investments	1,137	1,215	524.32	53.97
Cash Growth	30.70%	131.67%	871.44%	-
Accounts Receivable	14.14	15.11	1.17	-
Other Receivables	11.29	6.59	1.6	-
Receivables	25.43	21.7	2.77	-
Inventory	32.23	29.52	0.37	-
Prepaid Expenses	9.31	8.98	0.89	0.15
Other Current Assets	0.09	0.09	-	-
Total Current Assets	1,204	1,275	528.35	54.12
Property, Plant & Equipment	90.15	54.22	8.72	-
Long-Term Investments	2.65	4.92	-	-
Other Intangible Assets	0.48	0.36	-	-
Other Long-Term Assets	3.7	15.55	3.11	-
Total Assets	1,301	1,350	540.18	54.12
Accounts Payable	8.34	16.84	5.23	0.68
Accrued Expenses	14.58	12.41	3.39	4.65
Current Unearned Revenue	8.12	4.32	2.61	-
Other Current Liabilities	8.57	20.13	0.86	0.09
Total Current Liabilities	40.94	53.7	12.09	5.42
Total Liabilities	44.21	53.7	12.09	5.42
Common Stock	700	700	450.29	56
Additional Paid-In Capital	725.85	725.85	124.86	-
Retained Earnings	-178.14	-133.7	-47.44	-7.3
Comprehensive Income & Other	9.41	4.16	0.38	-
Shareholders' Equity	1,257	1,296	528.09	48.7
Total Liabilities & Equity	1,301	1,350	540.18	54.12
Net Cash (Debt)	1,133	1,215	524.32	53.97
Net Cash Growth	30.17%	131.67%	871.44%	-
Net Cash Per Share	16.78	21.15	34.74	49.29
Filing Date Shares Outstanding	70	70	70	1.1
Total Common Shares Outstanding	70	70	45.03	1.1
Working Capital	1,163	1,221	516.26	48.7
Book Value Per Share	17.96	18.52	11.73	44.47
Tangible Book Value	1,257	1,296	528.09	48.7
Tangible Book Value Per Share	17.95	18.51	11.73	44.47
Machinery	44.85	35.34	9.3	-
Construction In Progress	38.72	22.6	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.